Duodenal lymphocytosis

Microscopic Identity and Prevalence

Duodenal lymphocytosis—also referred to in the literature as lymphocytic duodenitis, lymphocytic duodenosis, or duodenal intraepithelial lymphocytosis—describes a histological finding rather than a single disease entity. When a pathologist examines a duodenal mucosal biopsy under the microscope, the hallmark is an elevated density of intra-epithelial lymphocytes (IELs) residing within the epithelial layer of the duodenum. The conventional threshold for calling this abnormal sits at roughly 20 to 25 IELs per 100 enterocytes.

These lymphocytes, predominantly T cells, are a normal resident population of the intestinal epithelium, with baseline numbers tending to be higher in the crypt regions and in the jejunum compared with the duodenum. They are anatomically and functionally distinct from the lymphocytes that populate the lamina propria beneath the epithelium. In routine practice, an IEL count above the threshold is encountered in approximately three percent of duodenal biopsies, though some series report figures climbing toward seven percent, suggesting the finding may be increasingly recognized as case mixes shift and counting techniques refine.

A Broad Differential: Beyond Coeliac Disease

Although duodenal lymphocytosis is most frequently discussed in the context of coeliac disease, the underlying aetiology is far from singular. The differential spans a wide spectrum of conditions. Tropical sprue and other forms of environmental enteropathy can provoke the same epithelial lymphocyte infiltration. Autoimmune enteropathy, small intestinal bacterial overgrowth, and mucosal injury from non-steroidal anti-inflammatory drugs all feature on the list.

Infectious agents play a notable role: Helicobacter pylori colonisation, Cryptosporidiosis, and Giardiasis have each been linked to elevated IEL counts. Crohn's disease, when it involves the duodenum, may also present with this histological pattern. In paediatric populations, Helicobacter infection is a common endoscopic finding, and while IEL counts tend to be marginally higher in its presence, clinicians have generally not regarded it as a meaningful driver of the lymphocytosis in children.

The breadth of this differential underscores that an elevated IEL count is a shared histological response to diverse mucosal insults rather than a pathognomonic marker of any one disease.

Treatment Pathways and Long-Term Outlook

Because duodenal lymphocytosis is a histological descriptor rather than a standalone disease, management is directed at whatever underlying condition is identified. In cases where coeliac disease is confirmed, a strict gluten-free diet remains the cornerstone of therapy, and this intervention has been shown to reduce IEL numbers over time. When an infection such as Helicobacter pylori, Cryptosporidium, or Giardia is the culprit, targeted antimicrobial or antiparasitic treatment addresses the root cause.

NSAID-related mucosal injury, by contrast, calls for withdrawal or substitution of the offending agent. The long-term prognosis hinges on whether the lymphocytosis is an isolated finding or a harbinger of evolving gluten sensitivity. In one prospective series of eighty-five patients, twenty-three progressed to overt coeliac disease within two years. Several clinical and serological features flagged those at higher risk: positive coeliac antibodies, the presence of HLA-DQ2 or HLA-DQ8, a family history of the condition, and accompanying symptoms such as chronic diarrhoea, thyroiditis, unexplained weakness, and folate deficiency.

Recognising these predictors allows clinicians to monitor more closely and intervene early, potentially preventing the full histological and nutritional consequences of established coeliac disease.